AIM ImmunoTech (AIM) Retained Earnings (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Retained Earnings came in at -$443.8 million in Q1 2026, down 204.03% YoY from $426.6 million in Q1 2025, and down 0.69% on a QoQ basis from -$440.8 million in Q4 2025.
AIM ImmunoTech (AIM) Retained Earnings (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Retained Earnings data on file, last reported at -$443.8 million in Q1 2026.
- Quarterly Retained Earnings fell 204.03% year-over-year to -$443.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$443.8 million (down 204.03% YoY) and the FY2025 annual result came in at -$440.8 million, down 3.27% from the prior year.
- Retained Earnings fell to -$443.8 million in Q1 2026, from -$440.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $426.6 million in Q1 2025 to a low of -$443.8 million in Q1 2026.
- A 5-year average of -$118.5 million and a median of -$380.5 million in 2022 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 217.69% in 2022, down 149605.26% in 2022.
- Tracing AIM's Retained Earnings over 5 years: stood at -$380.5 million in 2022, then decreased by 7.61% to -$409.5 million in 2023, then dropped by 4.23% to -$426.8 million in 2024, then declined by 3.27% to -$440.8 million in 2025, then retreated by 0.69% to -$443.8 million in 2026.
- The last three Retained Earnings figures came in at -$443.8 million (Q1 2026), -$440.8 million (Q4 2025), and -$436.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | 455.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 455.31 Mn |
| Mar 31, 2026 | -443.81 Mn |
| Dec 31, 2025 | -440.79 Mn |
| Sep 30, 2025 | -436.61 Mn |
| Jun 30, 2025 | -433.33 Mn |
| Mar 31, 2025 | 426.60 Mn |
| Dec 31, 2024 | -426.83 Mn |
| Sep 30, 2024 | 423.71 Mn |
| Jun 30, 2024 | -417.16 Mn |
| Mar 31, 2024 | -415.33 Mn |
| Dec 31, 2023 | -409.51 Mn |
| Sep 30, 2023 | 418.80 Mn |
| Jun 30, 2023 | 418.51 Mn |
| Mar 31, 2023 | 418.46 Mn |
| Dec 31, 2022 | -380.55 Mn |
| Sep 30, 2022 | 418.09 Mn |
| Jun 30, 2022 | -369.77 Mn |
| Mar 31, 2022 | -364.92 Mn |
| Dec 31, 2021 | -361.10 Mn |
| Sep 30, 2021 | -355.26 Mn |